Neurogene (NGNE) Stock Price, News & Analysis

Company Overview

Neurogene, Inc. is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues. Preclinical studies have demonstrated the potential for sustained biochemical correction and functional improvement, supporting the company’s progression into human clinical trials. Initial studies are under way in North America, and Neurogene plans to expand its clinical footprint into Europe pending regulatory clearances.

Headquartered in South San Francisco, California, Neurogene was founded to address the unmet needs of patients and families living with life-threatening genetic disorders of the nervous system. The company’s executive leadership team brings together expertise in gene therapy development, neurology, and biopharmaceutical manufacturing. By targeting diseases with well-defined genetic causes and no approved treatments, Neurogene aims to deliver transformative therapies to patients worldwide.

Key Stats

• Today's Range: $25.76 to $27.50
• 50-Day Range: $19.05 to $32.62
• 52-Week Range: $14.65 to $37.27
• Volume: 107,404 shs
• Average Volume: 132,203 shs
• Market Capitalization: $413.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $74.17
• Consensus Rating: Moderate Buy

Neurogene Stock Analysis - MarketRank™

Neurogene scored higher than 55% of companies evaluated by MarketBeat, and ranked 501st out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neurogene has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Neurogene has a consensus price target of $74.17, representing about 183.7% upside from its current price of $26.14.

Amount of Analyst Coverage

Neurogene has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Neurogene are expected to decrease in the coming year, from ($5.74) to ($5.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neurogene is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neurogene is -5.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neurogene has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.82% of the float of Neurogene has been sold short.

Short Interest Ratio / Days to Cover

Neurogene has a short interest ratio ("days to cover") of 24.65, which indicates bearish sentiment.

Change versus previous month

Short interest in Neurogene has recently decreased by 3.14%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neurogene does not currently pay a dividend.

Dividend Growth

Neurogene does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Neurogene has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Neurogene this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for NGNE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Neurogene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $525,622.00 in company stock.

Percentage Held by Insiders

11.68% of the stock of Neurogene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 6/02/2026
• AGM 2026: 6/03/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NGNE
• Previous Symbol: NASDAQ:NGNE
• CIK: 1404644
• Web: www.neurogene.com
• Phone: (877) 237-5020
• Fax: 778-331-4486
• Employees: 90
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Neurogene: $74.17
• High Price Target: $180.00
• Low Price Target: $26.00
• Potential Upside/Downside: +183.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$90.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.88%
• Return on Assets: -34.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.08
• Quick Ratio: 13.08

Sales & Book Value

• Annual Sales: $930 thousand
• Price / Sales: 444.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.10 per share
• Price / Book: 1.53

Miscellaneous

• Outstanding Shares: 15,800,000
• Free Float: 13,956,000
• Market Cap: $413.01 million
• Optionable: Optionable
• Beta: 1.69